VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5189 participants.
Also called NCT01130246
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,189 participants
- Sponsor
- Anthera Pharmaceuticals
- Registry
-
NCT01130246
-
- Other papers using this trial's data
- Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, Czechia, Georgia, Germany, Hungary, India, Italy, Lebanon, Netherlands, New Zealand, Poland, Russia, South Korea, Spain, Ukraine
- Registry status
- Terminated
Technical summary
Registry record NCT01130246. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
- Acronym
- VISTA-16
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- A-002, varespladib methyl
- Intervention (Drug)
- Placebo
- Lead sponsor
- Anthera Pharmaceuticals
Record details
- Record id
cardio:ct-nct01130246- Content hash
09b2102c413150fac32c0acd259f50c10e16dcd9965dddeba09b8aceb25312ff